Study of the stability of packaging and storage conditions of human mesenchymal stem cell for intra-arterial clinical application in patient with critical limb ischemia

dc.contributor.authorGálvez Martín, Patricia
dc.contributor.authorHmadcha, Abdelkrim
dc.contributor.authorSoria, Bernat
dc.contributor.authorCalpena Campmany, Ana Cristina
dc.contributor.authorClares Naveros, Beatriz
dc.date.accessioned2019-02-12T16:34:00Z
dc.date.available2019-02-12T16:34:00Z
dc.date.issued2014-04
dc.date.updated2019-02-12T16:34:00Z
dc.description.abstractCritical limb ischemia (CLI) is associated with significant morbidity and mortality. In this study, we developed and characterized an intra-arterial cell suspension containing human mesenchymal stem cells (hMSCs) for the treatment of CLI. Equally, the stability of cells was studied in order to evaluate the optimal conditions of storage that guarantee the viability from cell processing to the administration phase. Effects of various factors, including excipients, storage temperature and time were evaluated to analyze the survival of hMSCs in the finished medicinal product. The viability of hMSCs in different packaging media was studied for 60 h at 4 °C. The best medium to maintain hMSCs viability was then selected to test storage conditions (4, 8, 25 and 37 °C; 60 h). The results showed that at 4 °C the viability was maintained above 80% for 48 h, at 8 °C decreased slightly, whereas at room temperature and 37 °C decreased drastically. Its biocompatibility was assessed by cell morphology and cell viability assays. During stability study, the stored cells did not show any change in their phenotypic or genotypic characteristics and physicochemical properties remained constant, the ability to differentiate into adipocytes and osteocytes and sterility requirements were also unaltered. Finally, our paper proposes a packing media composed of albumin 20%, glucose 5% and Ringer's lactate at a concentration of 1 × 106 cells/mL, which must be stored at 4 °C as the most suitable to maintain cell viability (>80%) and without altering their characteristics for more than 48 h.
dc.format.extent10 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec630685
dc.identifier.issn0939-6411
dc.identifier.urihttps://hdl.handle.net/2445/128182
dc.language.isoeng
dc.publisherElsevier B.V.
dc.relation.isformatofVersió postprint del document publicat a: https://doi.org/10.1016/j.ejpb.2013.11.002
dc.relation.ispartofEuropean Journal of Pharmaceutics and Biopharmaceutics, 2014, vol. 86, num. 3, p. 459-468
dc.relation.urihttps://doi.org/10.1016/j.ejpb.2013.11.002
dc.rights(c) Elsevier B.V., 2014
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.sourceArticles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)
dc.subject.classificationIsquèmia
dc.subject.classificationCèl·lules mare
dc.subject.otherIschemia
dc.subject.otherStem cells
dc.titleStudy of the stability of packaging and storage conditions of human mesenchymal stem cell for intra-arterial clinical application in patient with critical limb ischemia
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/acceptedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
630685.pdf
Mida:
825.78 KB
Format:
Adobe Portable Document Format